Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
Recruiting
Observational Study
Pancreatic Cancer
Diabetes
Familial Pancreatic Cancer
Pancreatic Cystic Neoplasm
Chronic Pancreatitis
Hereditary Pancreatitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 5,000 (estimated)
- Sponsor
- Changhai Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only \~6%\[1\]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Subject is able and willing to provide informed consent and sign an informed consent form.
* Subject or authorized representative must be willing to complete a detailed questionnaire.
* Subject must meet one of the following criteria:
1. New onset diabetes (diagnosed within…
Contacts